A sweeping review of global research suggests that exercise—especially aerobic activities like running, swimming, and dancing—can be one of the most powerful ways to ease depression and anxiety.

Please provide your email address to receive an email when new articles are posted on . Adults with IDD used more medications for anxiety and depression than adults without IDD. Adults with IDD ...

I’ve seen it over and over. Couples come see me and begin recounting a litany of complaints about each other. They share painful experiences of feeling hurt, jealous, ignored, and unvalued. They ...

A US Senate committee has directed NASA to begin work on a moon base "as soon as is practicable." Under legislation advanced by the Senate lawmakers, the outpost would serve as a science laboratory ...

Background Cardiovascular disease (CVD) is the leading cause of mortality worldwide, while depression is highly prevalent in this patient population and has long been regarded as an independent risk ...

Biohaven Ltd BHVN shares were trading higher on Monday during the premarket session at as high as $12.52, before falling. The ...

Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update The ...

Exercise or relaxation—which truly lowers panic attacks? New research suggests one clearly outperforms the other, and the reason reveals a powerful key to lasting relief.

Accelerated repetitive transcranial magnetic stimulation appears to be effective for treatment-resistant depression.

Using brain scans and parent surveys, scientists discovered that infants in households struggling to make ends meet show delayed brain maturation. A mother's feeling of income insufficiency proved to ...

Samantha Teague receives funding from the National Health and Medical Research Council (NHMRC). James Dimmock, Klaire Somoray, and Neil Munro do not work for, consult, own shares in or receive funding ...

Xenon Pharmaceuticals (XENE) stock soared 40% after Phase 3 trial data for azetukalner exceeded expectations in focal onset seizures. FDA filing set for Q3 2026.